Food Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Allergen Type (Dairy Products, Poultry Product, Tree Nuts, Peanuts, Shellfish, Wheat, Soys, Other), By Drug Type (Antihistamines, Epinephrine, Immunotherapy), By Route of Administration (Oral, Parenteral, Other), By End User (Hospital Pharmacies, Retail Pharmacies, Others), By Region, & Competition, 2021-2031F

Market Overview

The Global Food Allergy Treatment Market will grow from USD 7.15 Billion in 2025 to USD 11.53 Billion by 2031 at a 8.29% CAGR. The Global Food Allergy Treatment Market encompasses the development and commercialization of pharmaceutical interventions and immunotherapies designed to desensitize the immune system or manage acute anaphylactic reactions caused by specific dietary proteins. The primary driver supporting market growth is the rapidly increasing global prevalence of sensitization to allergens such as peanuts, milk, and eggs, which generates urgent demand for effective clinical management strategies beyond avoidance. Additionally, the recent regulatory approval and introduction of biologic agents that facilitate desensitization are significantly propelling the sector by providing healthcare professionals with new mechanisms to mitigate reaction severity.

However, the market faces a significant challenge regarding the high cost of novel therapies and the complex reimbursement landscape which frequently restricts widespread patient access. These financial barriers often prevent ensuring equitable availability of life changing treatments across different demographic groups. According to Food Allergy Research & Education, in 2024, approximately 33 million people in the United States were living with life-threatening food allergies, highlighting a massive addressable market that remains partially constrained by affordability issues.

Key Market Drivers

The accelerated adoption of novel immunotherapies and biologics is fundamentally reshaping the Global Food Allergy Treatment Market, moving clinical care beyond simple avoidance strategies. This transition is anchored by recent regulatory milestones that provide healthcare professionals with the first pharmaceutical options designed to reduce reaction severity across multiple allergens simultaneously. According to Genentech, February 2024, in the 'FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies' press release, clinical trials demonstrated that 68% of patients treated with Xolair for 16 to 20 weeks could tolerate at least 600 mg of peanut protein without moderate to severe allergic symptoms, compared to only 5% of the placebo group. Such high efficacy data facilitates the rapid integration of biologic agents into standard treatment protocols, directly expanding the addressable market for therapeutic interventions.

Concurrently, the rising global prevalence of severe pediatric and adult food allergies is intensifying the urgency for these disease-modifying solutions. The market trajectory is heavily influenced by a patient population that faces life-threatening risks, creating a critical unmet need for treatments that prevent anaphylaxis. According to the Centers for Disease Control and Prevention, in 2024, at least 40% of children with food allergies have been treated in the emergency department for reactions, underscoring the severity of the condition. This high burden of disease drives substantial commercial activity and development expenditure; for instance, according to DBV Technologies, November 2024, in the 'Third Quarter 2024 Financial Results' report, operating expenses reached $96.4 million for the first nine months of the year, primarily to support the advancement of pivotal clinical trials.

Download Free Sample Report

Key Market Challenges

The high cost of novel therapies and the complex reimbursement landscape significantly impede the commercial expansion of the Global Food Allergy Treatment Market. While pharmaceutical advancements offer new desensitization mechanisms, the substantial research and development expenditures required for these biologics force manufacturers to set premium list prices. Consequently, health insurers often classify these treatments as non-essential or tier them with high out-of-pocket costs, creating a financial barrier that restricts patient adoption. This disconnect between clinical availability and economic accessibility limits the serviceable addressable market, as only a fraction of the diagnosed population can afford continuous therapy, thereby stalling revenue growth for manufacturers.

This financial friction is further compounded by the existing economic burden placed on families managing these conditions. According to the Asthma and Allergy Foundation of America, in 2025, the inflation-adjusted annual economic cost of caring for children with food allergies was estimated to be approximately $34 billion. This substantial figure illustrates the heavy financial load already borne by households, making the additional expense of high-priced pharmaceutical interventions untenable for many. As a result, the market struggles to convert high clinical demand into sustained therapeutic adoption.

Key Market Trends

The emergency response segment is witnessing a significant shift away from traditional auto-injectors toward needle-free alternatives, specifically the commercialization of intranasal epinephrine sprays. This trend directly addresses critical barriers such as needle phobia and device bulkiness, which have historically delayed the administration of life-saving medication during anaphylactic events. Manufacturers are currently leveraging aggressive pricing strategies and partnership models to ensure these novel delivery systems rapidly penetrate the market and become accessible to a broad patient base. For instance, according to GoodRx, September 2024, in the 'GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy' press release, a strategic partnership was established to allow consumers to access a pack of two single-use neffy devices for $199 at over 70,000 pharmacies, significantly lowering the financial hurdle for this new technology.

Simultaneously, the market is experiencing a surge in the development of Epicutaneous Immunotherapy (EPIT) platforms, which deliver micro-doses of allergens through the skin to induce tolerance with fewer systemic side effects than oral routes. This non-invasive approach is rapidly advancing through late-stage clinical pipelines, aiming to provide a safer desensitization option for pediatric patients who may not tolerate the gastrointestinal side effects associated with oral immunotherapy. Reflecting the substantial scale of this clinical development, according to DBV Technologies, October 2024, in the 'DBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch' press release, the company successfully enrolled a total of 654 subjects in the Phase 3 VITESSE efficacy trial to evaluate the modified peanut patch in children.

Segmental Insights

The Epinephrine segment is the fastest growing category in the Global Food Allergy Treatment Market because it functions as the primary emergency intervention for anaphylaxis. This growth is accelerated by the development of novel delivery systems, including needle-free nasal sprays, which address patient hesitation regarding traditional auto-injectors. Regulatory bodies such as the U.S. Food and Drug Administration have supported this expansion by approving advanced formulations that improve ease of use. Furthermore, the rising global incidence of severe food reactions maintains a critical reliance on epinephrine, solidifying its status as the standard of care for immediate allergy management.

Regional Insights

North America maintains a leading position in the global food allergy treatment market, driven by a high prevalence of allergic conditions and strong healthcare infrastructure. This dominance is supported by substantial investment in clinical research and the presence of major pharmaceutical companies developing new therapies. Additionally, proactive measures by the U.S. Food and Drug Administration (FDA) in accelerating drug approvals encourage market growth. Favorable reimbursement structures and increased patient awareness regarding diagnosis and management further solidify the region's status as a primary revenue generator in this sector.

Recent Developments

• In October 2024, DBV Technologies announced positive regulatory updates regarding its Viaskin Peanut patch, a proprietary epicutaneous immunotherapy being developed for the Global Food Allergy Treatment Market. The company confirmed that it had reached an agreement with the U.S. FDA on a pathway to pursue accelerated approval for the treatment in toddlers aged one to three years. This alignment followed productive discussions concerning the design of supplemental safety studies required for the biologics license application. The Chief Executive Officer of DBV Technologies stated that this regulatory clarity was a crucial step toward bringing their non-invasive patch technology to young patients who currently lack sufficient treatment options for peanut allergies.
• In August 2024, ARS Pharmaceuticals received U.S. FDA approval for neffy (epinephrine nasal spray), introducing the first needle-free emergency treatment for Type I allergic reactions, including anaphylaxis. This product launch represented a major innovation in the Global Food Allergy Treatment Market, offering a user-friendly alternative to traditional auto-injectors for adults and children weighing at least 30 kilograms. The approval followed clinical studies demonstrating that the nasal spray achieved epinephrine blood concentrations comparable to approved injectable products. The company highlighted that this novel delivery method would empower patients and caregivers to administer life-saving treatment more confidently and rapidly, potentially improving outcomes during severe allergic events.
• In July 2024, Stallergenes Greer announced that the U.S. FDA had expanded the approved indication for Palforzia to include toddlers aged one to three years with a confirmed diagnosis of peanut allergy. This regulatory development addressed a critical unmet need in the Global Food Allergy Treatment Market, providing the first approved oral immunotherapy option for this younger demographic. The approval was based on results from the Phase 3 POSEIDON study, which evaluated the safety and efficacy of the treatment in young children. The Chief Medical Officer of Stallergenes Greer noted that this indication extension would help alleviate the burden of peanut allergy for families by mitigating the risk of severe reactions from accidental exposure to peanuts.
• In February 2024, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) had approved Xolair (omalizumab) for the reduction of allergic reactions, including anaphylaxis, in patients aged one year and older with IgE-mediated food allergy. This approval marked a significant milestone in the Global Food Allergy Treatment Market as Xolair became the first and only FDA-approved medicine designed to reduce allergic reactions across multiple food allergies. The decision was supported by data from the Phase III OUtMATCH study, which demonstrated that a significantly higher proportion of patients treated with the drug could tolerate small amounts of peanut, milk, egg, and cashew without experiencing an allergic reaction compared to those who received a placebo.

Key Market Players

• Aimmune Therapeutics
• DBV Technologies
• Regeneron
• Sanofi
• Nestlé Health Science
• Novartis
• Immune Design
• TanGenix
• Allergen Labs
• FARE-associated Innovators

Report Scope:

In this report, the Global Food Allergy Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Food Allergy Treatment Market, By Allergen Type:

• Dairy Products
• Poultry Product
• Tree Nuts
• Peanuts
• Shellfish
• Wheat
• Soys
• Other

• Food Allergy Treatment Market, By Drug Type:

• Antihistamines
• Epinephrine
• Immunotherapy

• Food Allergy Treatment Market, By Route of Administration:

• Oral
• Parenteral
• Other

• Food Allergy Treatment Market, By End User:

• Hospital Pharmacies
• Retail Pharmacies
• Others

• Food Allergy Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE